Evaluation of the clinical and anti-destructive effect of an anti-B cell preparation depending on concomitant therapy with basic anti-inflammatory drugs and glucocorticoids in patients with rheumatoid arthritis
Aim: To evaluate the effectiveness, safety and anti-destructive effect of anti-B-cell therapy (rituximab) in various combinations (RTM-mono, RTM + DMARD, RTM + GK) in patients with rheumatoid arthritis in real clinical practice.Materials and methods: Clinical and radiological evaluation of 110 patie...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2019-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/5003 |
id |
doaj-18b8b4890967419ebed7d7a35259f5a9 |
---|---|
record_format |
Article |
spelling |
doaj-18b8b4890967419ebed7d7a35259f5a92021-07-28T13:29:43ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902019-12-0101811011710.21518/2079-701X-2019-18-110-1174541Evaluation of the clinical and anti-destructive effect of an anti-B cell preparation depending on concomitant therapy with basic anti-inflammatory drugs and glucocorticoids in patients with rheumatoid arthritisA. V. Kudryavtseva0G. V. Lukina1A. V. Smirnov2S. I. Glukhova3Federal State Budgetary Institution «Research Institute of Rheumatology named after V.A. Nasonova»Federal State Budgetary Institution «Research Institute of Rheumatology named after V.A. Nasonova»Federal State Budgetary Institution «Research Institute of Rheumatology named after V.A. Nasonova»Federal State Budgetary Institution «Research Institute of Rheumatology named after V.A. Nasonova»Aim: To evaluate the effectiveness, safety and anti-destructive effect of anti-B-cell therapy (rituximab) in various combinations (RTM-mono, RTM + DMARD, RTM + GK) in patients with rheumatoid arthritis in real clinical practice.Materials and methods: Clinical and radiological evaluation of 110 patients with rheumatoid arthritis who received rituximab therapy (RTM) as monotherapy (group 1), in combination with methotrexate (group 2), leflunomide (group 3), and group 4 with other basic anti-inflammatory drugs.Results: When assessing at 48 weeks of treatment with these regimens, the achievement of remission and a low degree of activity was observed in 22.36% of patients. An X-ray evaluation showed the absence of progression in the total score in 60.9%. When assessing progression in the monotherapy group, there was no progression in 76.92%, in the group of PTM + MT – in 54.29%, in the group of PTM + LEF – 65.0%, in the group of other DMARDs – 50% of patients. When assessing the clinical effect in the group receiving GK – remission and a low degree of activity – 19.67% of patients, in the group without GK – 21.05%. Assessing the radiological dynamics, it was shown that in the group not receiving GK – inhibition by the total score occurred in 54.55%, receiving – 61.54%.Conclusion: This work has demonstrated the high therapeutic efficacy of RTM in real clinical practice. There were no significant differences in the degree of progression depending on the concomitant therapy of DMARDs or GK. In the treatment of RTM, inhibition of articular destruction is possible even against the background of clinical deterioration.https://www.med-sovet.pro/jour/article/view/5003rheumatoid arthritisrituximabdmardsglucocorticoidsclinical effectbone destruction |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
A. V. Kudryavtseva G. V. Lukina A. V. Smirnov S. I. Glukhova |
spellingShingle |
A. V. Kudryavtseva G. V. Lukina A. V. Smirnov S. I. Glukhova Evaluation of the clinical and anti-destructive effect of an anti-B cell preparation depending on concomitant therapy with basic anti-inflammatory drugs and glucocorticoids in patients with rheumatoid arthritis Медицинский совет rheumatoid arthritis rituximab dmards glucocorticoids clinical effect bone destruction |
author_facet |
A. V. Kudryavtseva G. V. Lukina A. V. Smirnov S. I. Glukhova |
author_sort |
A. V. Kudryavtseva |
title |
Evaluation of the clinical and anti-destructive effect of an anti-B cell preparation depending on concomitant therapy with basic anti-inflammatory drugs and glucocorticoids in patients with rheumatoid arthritis |
title_short |
Evaluation of the clinical and anti-destructive effect of an anti-B cell preparation depending on concomitant therapy with basic anti-inflammatory drugs and glucocorticoids in patients with rheumatoid arthritis |
title_full |
Evaluation of the clinical and anti-destructive effect of an anti-B cell preparation depending on concomitant therapy with basic anti-inflammatory drugs and glucocorticoids in patients with rheumatoid arthritis |
title_fullStr |
Evaluation of the clinical and anti-destructive effect of an anti-B cell preparation depending on concomitant therapy with basic anti-inflammatory drugs and glucocorticoids in patients with rheumatoid arthritis |
title_full_unstemmed |
Evaluation of the clinical and anti-destructive effect of an anti-B cell preparation depending on concomitant therapy with basic anti-inflammatory drugs and glucocorticoids in patients with rheumatoid arthritis |
title_sort |
evaluation of the clinical and anti-destructive effect of an anti-b cell preparation depending on concomitant therapy with basic anti-inflammatory drugs and glucocorticoids in patients with rheumatoid arthritis |
publisher |
Remedium Group LLC |
series |
Медицинский совет |
issn |
2079-701X 2658-5790 |
publishDate |
2019-12-01 |
description |
Aim: To evaluate the effectiveness, safety and anti-destructive effect of anti-B-cell therapy (rituximab) in various combinations (RTM-mono, RTM + DMARD, RTM + GK) in patients with rheumatoid arthritis in real clinical practice.Materials and methods: Clinical and radiological evaluation of 110 patients with rheumatoid arthritis who received rituximab therapy (RTM) as monotherapy (group 1), in combination with methotrexate (group 2), leflunomide (group 3), and group 4 with other basic anti-inflammatory drugs.Results: When assessing at 48 weeks of treatment with these regimens, the achievement of remission and a low degree of activity was observed in 22.36% of patients. An X-ray evaluation showed the absence of progression in the total score in 60.9%. When assessing progression in the monotherapy group, there was no progression in 76.92%, in the group of PTM + MT – in 54.29%, in the group of PTM + LEF – 65.0%, in the group of other DMARDs – 50% of patients. When assessing the clinical effect in the group receiving GK – remission and a low degree of activity – 19.67% of patients, in the group without GK – 21.05%. Assessing the radiological dynamics, it was shown that in the group not receiving GK – inhibition by the total score occurred in 54.55%, receiving – 61.54%.Conclusion: This work has demonstrated the high therapeutic efficacy of RTM in real clinical practice. There were no significant differences in the degree of progression depending on the concomitant therapy of DMARDs or GK. In the treatment of RTM, inhibition of articular destruction is possible even against the background of clinical deterioration. |
topic |
rheumatoid arthritis rituximab dmards glucocorticoids clinical effect bone destruction |
url |
https://www.med-sovet.pro/jour/article/view/5003 |
work_keys_str_mv |
AT avkudryavtseva evaluationoftheclinicalandantidestructiveeffectofanantibcellpreparationdependingonconcomitanttherapywithbasicantiinflammatorydrugsandglucocorticoidsinpatientswithrheumatoidarthritis AT gvlukina evaluationoftheclinicalandantidestructiveeffectofanantibcellpreparationdependingonconcomitanttherapywithbasicantiinflammatorydrugsandglucocorticoidsinpatientswithrheumatoidarthritis AT avsmirnov evaluationoftheclinicalandantidestructiveeffectofanantibcellpreparationdependingonconcomitanttherapywithbasicantiinflammatorydrugsandglucocorticoidsinpatientswithrheumatoidarthritis AT siglukhova evaluationoftheclinicalandantidestructiveeffectofanantibcellpreparationdependingonconcomitanttherapywithbasicantiinflammatorydrugsandglucocorticoidsinpatientswithrheumatoidarthritis |
_version_ |
1721273671979368448 |